Print Clear

Prior Authorization Request Administrative Information

Member Information

Last name _____ First name _____ MI _____

Member ID _____ Date of birth _____

Sex assigned at birth ☐ Female ☐ Male ☐ "X" or Intersex

Current gender ☐ Female ☐ Male ☐ Transgender male ☐ Transgender female ☐ Other _____

Place of residence ☐ Home ☐ Nursing facility ☐ Other _____

Race/ethnicity _____ Preferred spoken language _____ Preferred written language _____

MassHealth does not exclude people or treat them differently because of race, color, national origin, age, disability, religion, creed, sexual orientation, or sex (including gender identity and gender stereotyping).

Plan Contact Information

Please indicate the member's MassHealth Plan and fax or submit this completed and signed form according to the Plan's contact information below.

MassHealth Fee-For-Service (FFS) Plan, Primary Care Clinician (PCC) Plan, Primary Care Accountable Care Organization (PCACO) Plan, Children's Medical Security Plan, and Health Safety Net Plan
☐ **MassHealth Drug Utilization Review Program** Pharmacy: Fax: (877) 208-7428 - Tel: (800) 745-7318
MassHealth Managed Care Organization (MCO) and Accountable Care Partnership Plans (ACPP)
☐ **Fallon Health** Online Prior Authorization: go.covermymeds.com/OptumRx Online Prior Authorization: providerportal.surescripts.net/ProviderPortal/optum Pharmacy: Fax: (844) 403-1029 - Tel: (844) 720-0033
☐ **Health New England** Online Prior Authorization: go.covermymeds.com/OptumRx Pharmacy: Fax: (800) 550-9246 - Tel: (800) 918-7545
☐ **Mass General Brigham Health Plan** Online Prior Authorization (Non-Specialty Drugs): go.covermymeds.com/OptumRx Online Prior Authorization (Specialty/Medical Drugs): provider.massgeneralbrighamhealthplan.org Pharmacy: Fax: (844) 403-1029 - Tel: (800) 711-4555
☐ **Tufts Health Plan** Online Prior Authorization: point32health.promptpa.com Pharmacy: Fax: (617) 673-0939 - Tel: (888) 257-1985
☐ **WellSense Health Plan** Online Prior Authorization: wellsense.org/providers/ma/pharmacy/prior-authorizations Pharmacy: Fax: (833) 951-1680 - Tel: (877) 417-1822

over

Proton Pump Inhibitor
Prior Authorization Request

MassHealth reviews requests for prior authorization (PA) on the basis of medical necessity only. If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including current member eligibility, other insurance, and program restrictions. MassHealth will notify the requesting provider and member of its decision. Keep a copy of this form for your records. If faxing this form, please use black ink.

Additional information about these agents, including PA requirements and preferred products, can be found within the MassHealth Drug List at **www.mass.gov/druglist.**

Medication information

Medication requested

- ☐ Aciphex Sprinkle (rabeprazole delayed release capsule)
- ☐ esomeprazole magnesium capsule > 1 unit/day
- ☐ esomeprazole magnesium 2.5 mg, 5 mg suspension
- ☐ esomeprazole sodium IV
- ☐ First-Omeprazole (omeprazole suspension compounding kit)
- ☐ Konvomep (omeprazole/sodium bicarbonate suspension)
- ☐ lansoprazole capsule > 1 unit/day
- ☐ lansoprazole orally disintegrating tablet (≥ 2 years of age)
- ☐ omeprazole 10 mg > 1 unit/day
- ☐ omeprazole 20 mg > 4 units/day
- ☐ omeprazole 40 mg > 2 units/day
- ☐ omeprazole/sodium bicarbonate powder for oral suspension
- ☐ pantoprazole tablet > 4 units/day
- ☐ Prilosec (omeprazole suspension)
- ☐ pantoprazole 40 mg suspension
- ☐ rabeprazole delayed-release tablet > 1 unit/day

Dose and frequency of requested agent

Intended duration of therapy

Indication (Check all that apply or include ICD-10 code, if applicable)

- ☐ **GERD**
  - ☐ Moderate-severe erosive esophagitis
  - ☐ Uncomplicated nonerosive esophagitis
  - ☐ Barrett's esophagus
  - ☐ GERD in child with one of the following conditions
    - ☐ Severe chronic respiratory disease (specify)
    - ☐ Neurologic disability (specify)
    - ☐ Other (specify)
- ☐ **Condition associated with extraesophageal symptoms secondary to gastric reflux**
  - ☐ Noncardiac chest pain
  - ☐ Asthma
  - ☐ Idiopathic hoarseness
  - ☐ Chronic laryngitis
  - ☐ Other (explain)
- ☐ **Duodenal ulcer**
  - ☐ Helicobacter pylori
  - ☐ Drug-induced
  - ☐ Treatment. List causative agent(s).
  - ☐ Prevention. List risk factor(s).
  - ☐ Other cause (specify)
- ☐ **Gastric ulcer**
  - ☐ Positive
  - ☐ Negative

☐ **Pathological hypersecretory syndromes**
- ☐ Zollinger-Ellison syndrome
- ☐ MEN Type I
- ☐ Other

☐ Other (explain)

Diagnostic studies performed (include dates of studies). Describe any diagnostic studies performed, including dates of studies.

Section I. Please complete for requests for Aciphex Sprinkle, esomeprazole magnesium 2.5 mg and 5 mg suspension, lansoprazole orally disintegrating tablet, Prilosec suspension, and pantoprazole 40 mg suspension.

Has the member had a trial with esomeprazole magnesium capsule, lansoprazole capsule, omeprazole, pantoprazole, or rabeprazole tablet?

☐ Yes. Please list the specific drug name, dates/duration of use, and outcomes below.

Drug name, dose and frequency Dates/duration of use

Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response ☐ Other

Briefly describe details of adverse reaction, inadequate response, or other.

Drug name, dose and frequency Dates/duration of use

Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response ☐ Other

Briefly describe details of adverse reaction, inadequate response, or other.

☐ No. Please describe clinical rationale why these trials are not appropriate for this member.

Section II. Please complete for requests for omeprazole 20 mg capsules and pantoprazole tablets at quantities > 4 units/day, omeprazole 40 mg capsules > 2 units/day, and any other oral proton pump inhibitor at quantities > 1 unit/day.

Please describe medical necessity for use above the established quantity limits.

Section III. Please complete for requests for esomeprazole sodium IV and First-Omeprazole.

1. Please describe medical necessity for use of the requested formulation.
2. For esomeprazole sodium IV, has the member had a trial with pantoprazole IV?
   ☐ Yes. Please list dates/duration of use and outcomes below.

   Dates/duration of use

   Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response ☐ Other

over

☐ No. Please describe clinical rationale why pantoprazole IV is not appropriate for this member.

Section IV. Please complete for requests for Konvomep and omeprazole/sodium bicarbonate powder for oral suspension.

1. Has the member had a trial with esomeprazole suspension, lansoprazole orally disintegrating tablet, omeprazole capsule, or pantoprazole suspension?
   ☐ Yes. Please list the specific drug name, dates/duration of use, and outcomes below.

   Drug name, dose, and frequency Dates/duration of use
   Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response ☐ Other
   Briefly describe details of adverse reaction, inadequate response, or other.

   Drug name, dose, and frequency Dates/duration of use
   Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response
   Briefly describe details of adverse reaction, inadequate response, or other.

   Drug name, dose, and frequency Dates/duration of use
   Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response
   Briefly describe details of adverse reaction, inadequate response, or other.

   ☐ No. Please describe clinical rationale why these trials are not appropriate for this member.
2. Please describe medical necessity for use of the requested formulation.

Section V. Please complete and provide documentation for exceptions to Step Therapy.

1. Is the alternative drug required under the step therapy protocol contraindicated, or will likely cause an adverse reaction in, or physical or mental harm to the member? ☐ Yes ☐ No
   If yes, briefly describe details of contraindication, adverse reaction, or harm.
2. Is the alternative drug required under the step therapy protocol expected to be ineffective based on the known clinical characteristics of the member and the known characteristics of the alternative drug regimen?
   ☐ Yes ☐ No
   If yes, briefly describe details of known clinical characteristics of member and alternative drug regimen.
3. Has the member previously tried the alternative drug required under the step therapy protocol, or another alternative drug in the same pharmacologic class or with the same mechanism of action, and such alternative drug was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event?
   ☐ Yes ☐ No
   If yes, please provide details for the previous trial.

   Drug name Dates/duration of use

over

Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response
Briefly describe details of adverse reaction or inadequate response.

4. Is the member stable on the requested prescription drug prescribed by the health care provider, and switching drugs will likely cause an adverse reaction in or physical or mental harm to the member?

☐ Yes. Please provide details.
☐ No

Please continue to next page and complete Prescriber and Provider Information section.

over

Prior Authorization Request Prescriber and Provider Information

Prescriber Information

Last name* First name* MI

NPI* Individual MH Provider ID

DEA No. Office Contact Name

Address City State Zip

Email address

Telephone No.* Fax No.*

** Required*

Please also complete for professionally administered medications, if applicable.

Start date End date

Servicing prescriber/facility name ☐ Same as prescribing provider

Servicing provider/facility address

Servicing provider NPI/tax ID No.

Name of billing provider

Billing provider NPI No.

Is this a request for recertification? ☐ Yes ☐ No

CPT code No. of visits J code No. of units

Prescribing provider's attestation, signature, and date

I certify under the pains and penalties of perjury that I am the prescribing provider identified in the Prescriber information section of this form. Any attached statement on my letterhead has been reviewed and signed by me. I certify that the medical necessity information (per 130 CMR 450.204) on this form is true, accurate, and complete, to the best of my knowledge. I understand that I may be subject to civil penalties or criminal prosecution for any falsification, omission, or concealment of any material fact contained herein.

Prescribing provider's signature _____

Printed name of prescribing provider Date

(The form can either be signed by hand and then scanned, or it can be signed electronically using DocuSign or Adobe Sign. For electronic signatures, the signer can upload a picture of their wet signature. The typed text of a signature is not an acceptable form of an electronic signature.)